Lanadelumab
Mechanism :
Human monoclonal antibody (IgG1/K-light chain) that binds plasma kallikrein and inhibits its proteolytic activity, controlling excess bradykinin generation in patients with hereditary angioedema.
Indication :
- Prophylaxis of hereditary angioedema
Contraindications :
No contraindications.
Dosing :
Prophylaxis of hereditary angioedema:
Children ≥12 years of age and adolescents:
Subcutaneous:
Initial: 300 mg every 2 weeks; dosing every 4 weeks may be considered in patients well-controlled (e.g., attack free) for >6 months.
Adverse Effect :
Headache, antibody development, injection site reactions, myalgia, upper respiratory tract infections, dizziness, skin rash, diarrhea, hypersensitivity.
Interaction :
No known significant interactions.
Hepatic Dose :
No dose adjustments are recommended.